Is this e-mail not displaying correctly? View this e-mail in your browser.
Interested in FREE samples of BESIVANCE®?

Indication

BESIVANCE® is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans,* CDC coryneform group G, Corynebacterium pseudodiphtheriticum,* Corynebacterium striatum,* Haemophilus influenzae, Moraxella catarrhalis,* Moraxella lacunata,* Pseudomonas aeruginosa,* Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis,* Staphylococcus lugdunensis,* Staphylococcus warneri,* Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections.
  • Powerful and effective treatment of the pathogens
    of greater concern1-3
    Now indicated for Pseudomonas aeruginosa conjunctivitis
  • Provides long-lasting tear concentrations3-5
  • The first and only topical ophthalmic
    chlorofluoroquinolone1
    BESIVANCE® is a dual-halogenated fluoroquinolone that
    provides potent inhibition of bacterial DNA replication1

Important Risk Information about BESIVANCE®

  • BESIVANCE® is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
  • As with other anti-infectives, prolonged use of BESIVANCE® may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE®.
  • The most common adverse event reported in 2% of patients treated with BESIVANCE® was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE® occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
  • BESIVANCE® is not intended to be administered systemically. Quinolones administered systemically have been associated with hypersensitivity reactions, even following a single dose. Patients should be advised to discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction.
  • Safety and effectiveness in infants below one year of age have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see complete information about BESIVANCE® in the full prescribing
information provided here.
References: 1. BESIVANCE Prescribing Information, September 2012. 2. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159-1169. 3. Data on file, Bausch & Lomb Incorporated. 4. Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25(4):335-343. 5. Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol. 2011;5:1369-1379.

For product-related questions and concerns, call 1-800-323-0000 or visit www.besivance.com.

If you no longer wish to receive e-mails from Bausch + Lomb about BESIVANCE®, unsubscribe here.

BESIVANCE is a registered trademark of Bausch & Lomb Incorporated.

©2012 Bausch & Lomb Incorporated. PH4687 9/12